Cargando…

Identification of the SARS-unique domain of SARS-CoV-2 as an antiviral target

SARS-CoV-2 nsp3 is essential for viral replication and host responses. The SARS-unique domain (SUD) of nsp3 exerts its function through binding to viral and host proteins and RNAs. Herein, we show that SARS-CoV-2 SUD is highly flexible in solution. The intramolecular disulfide bond of SARS-CoV SUD i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qin, Bo, Li, Ziheng, Tang, Kaiming, Wang, Tongyun, Xie, Yubin, Aumonier, Sylvain, Wang, Meitian, Yuan, Shuofeng, Cui, Sheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326071/ https://www.ncbi.nlm.nih.gov/pubmed/37414753 http://dx.doi.org/10.1038/s41467-023-39709-6

Ejemplares similares

SARS-CoV-2 Antiviral Therapy
por: Tao, Kaiming, et al.
Publicado: (2021)

Crystal structure of SARS-CoV-2 papain-like protease
por: Gao, Xiaopan, et al.
Publicado: (2021)

Crystal structure of SARS-CoV-2 Orf9b in complex with human TOM70 suggests unusual virus-host interactions
por: Gao, Xiaopan, et al.
Publicado: (2021)

Binding of the SARS-CoV-2 spike protein to glycans
por: Hao, Wei, et al.
Publicado: (2021)

Sierra SARS-CoV-2 sequence and antiviral resistance analysis program
por: Tzou, Philip L., et al.
Publicado: (2022)

Effect of Different Adjuvants on Immune Responses Elicited by Protein-Based Subunit Vaccines against SARS-CoV-2 and Its Delta Variant
por: Zhang, Naru, et al.
Publicado: (2022)

The SARS‐unique domain (SUD) of SARS‐CoV and SARS‐CoV‐2 interacts with human Paip1 to enhance viral RNA translation
por: Lei, Jian, et al.
Publicado: (2021)

Identification of hACE2-interacting sites in SARS-CoV-2 spike receptor binding domain for antiviral drugs screening
por: Hu, Xiaopeng, et al.
Publicado: (2022)

SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries
por: Elshabrawy, Hatem A.
Publicado: (2020)

The “SARS-unique domain” (SUD) of SARS coronavirus is an oligo(G)-binding protein
por: Tan, Jinzhi, et al.
Publicado: (2007)

Unique Mode of Antiviral Action of a Marine Alkaloid against Ebola Virus and SARS-CoV-2
por: Izumida, Mai, et al.
Publicado: (2022)

A Uniquely Stable Trimeric Model of SARS-CoV-2 Spike Transmembrane Domain
por: Aliper, Elena T., et al.
Publicado: (2022)

Theory and reality of antivirals against SARS-CoV-2
por: Zhao, Bo, et al.
Publicado: (2021)

Immune evasion of SARS-CoV-2 from interferon antiviral system
por: Min, Yuan-Qin, et al.
Publicado: (2021)

Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2
por: Xiao, Xia, et al.
Publicado: (2020)

SARS-CoV-2 cell entry and targeted antiviral development
por: Chen, Zinuo, et al.
Publicado: (2021)

Reverse genetic systems of SARS-CoV-2 for antiviral research
por: Kurhade, Chaitanya, et al.
Publicado: (2023)

The SARS-Unique Domain (SUD) of SARS Coronavirus Contains Two Macrodomains That Bind G-Quadruplexes
por: Tan, Jinzhi, et al.
Publicado: (2009)

Antiviral drug design based on structural insights into the N-terminal domain and C-terminal domain of the SARS-CoV-2 nucleocapsid protein
por: Luan, Xiaodong, et al.
Publicado: (2022)

SARS-CoV-2 membrane glycoprotein M antagonizes the MAVS-mediated innate antiviral response
por: Fu, Yu-Zhi, et al.
Publicado: (2020)

SARS Coronavirus Unique Domain: Three-Domain Molecular Architecture in Solution and RNA Binding
por: Johnson, Margaret A., et al.
Publicado: (2010)

The Spike of SARS-CoV-2: Uniqueness and Applications
por: Kumavath, Ranjith, et al.
Publicado: (2021)

Fuzzy optimization for identifying antiviral targets for treating SARS-CoV-2 infection in the heart
por: Chu, Sz-Wei, et al.
Publicado: (2023)

Aminoglycosides and their potential as SARS-CoV-2 antivirals
por: Cimolai, Nevio
Publicado: (2021)

Sars-Cov-2 and risk of antiviral drug resistance
por: Vitiello, Antonio
Publicado: (2021)

SARS-CoV-2 rebound with and without antivirals
por: Petrosillo, Nicola
Publicado: (2023)

Antiviral drugs against SARS-CoV-2
por: Aiello, Tommaso Francesco, et al.
Publicado: (2022)

Identification of Human Single-Domain Antibodies against SARS-CoV-2
por: Wu, Yanling, et al.
Publicado: (2020)

Crystal structure of the NS3-like helicase from Alongshan virus
por: Gao, Xiaopan, et al.
Publicado: (2020)

The spike receptor-binding motif G496S substitution determines the replication fitness of SARS-CoV-2 Omicron sublineage
por: Liang, Ronghui, et al.
Publicado: (2022)

Monovalent vaccination with inactivated SARS-CoV-2 BA.5 protects hamsters against Omicron but not non-Omicron variants
por: Ong, Chon Phin, et al.
Publicado: (2023)

SARS-CoV-2 exploits host DGAT and ADRP for efficient replication
por: Yuan, Shuofeng, et al.
Publicado: (2021)

SARS-CoV-2 replicon for high-throughput antiviral screening
por: Zhang, Qiu-Yan, et al.
Publicado: (2021)

Identification of antiviral peptide inhibitors for receptor binding domain of SARS-CoV-2 omicron and its sub-variants: an in-silico approach
por: Singh, Swati, et al.
Publicado: (2022)

Identification of motif-based interactions between SARS-CoV-2 protein domains and human peptide ligands pinpoint antiviral targets
por: Mihalič, Filip, et al.
Publicado: (2023)

Clinical Trials of Repurposed Antivirals for SARS-CoV-2
por: Martinez, Miguel Angel
Publicado: (2020)

SARS-CoV-2 and the Use of Chloroquine as an Antiviral Treatment
por: Rebeaud, Mathieu E., et al.
Publicado: (2020)

Host proviral and antiviral factors for SARS-CoV-2
por: Lv, Lu, et al.
Publicado: (2021)

Mechanisms of Antiviral Immune Evasion of SARS-CoV-2
por: Beyer, Daniel K., et al.
Publicado: (2022)

Antiviral Effect of Budesonide against SARS-CoV-2
por: Heinen, Natalie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e9p5ap428jokvik88395fjh77g